Progress in Mind Go to Progress in Mind Main channel featuring interviews, articles, congress highlights and much more. Go to channel
Lundbeck Institute Campus. Go to Lundbeck Institute Campus. Medical education resource center in psychiatry and neurology. Go to channel
Schizophrenia Congress highlights Expert guidance on management of schizophrenia for a better quality of life and independence Individualized patient management is key to achieving better lifetime quality of life and... Content action menuShareTestTest 2Test 3
Depression Congress highlights Early effects of antidepressants – a clue to mechanism of action The delay in onset of effect of antidepressant treatment can be frustrating both for the patient... Content action menuShareTestTest 2Test 3
Depression, Bipolar Congress highlights In search of biomarkers for mood disorders Novel biomarkers for mood disorders will enable early diagnosis and inform the development of new... Content action menuShareTestTest 2Test 3
Mental health Congress highlights A public invitation to view and comment on pre-final APA schizophrenia guideline statements Many guidelines exist worldwide on how best to manage psychiatric illnesses, but we never see two... Content action menuShareTestTest 2Test 3
Depression, Schizophrenia Congress highlights Lifestyle, the gut, and mental health Interventions to lower the risk for cardiovascular disease and metabolic syndrome, correction of... Content action menuShareTestTest 2Test 3
Schizophrenia Article Positive steps to address negative symptoms in schizophrenia A goal of precision psychiatry is to locate a patient along the continuum of the disease course,... Content action menuShareTestTest 2Test 3
Schizophrenia Article The effects of antipsychotic dose reduction/discontinuation on long-term outcome in FEP patients Patients with FEP often ask whether they can discontinue their medication after a period of... Content action menuShareTestTest 2Test 3
Depression Article Does glutamate hold the key to unlocking major depressive disorder? Despite over 50 years of drug development in major depressive disorder (MDD), patients and their... Content action menuShareTestTest 2Test 3
Schizophrenia Congress highlights Dopamine D2 partial agonists – efficacy, tolerability and improved functioning? ‘Functioning’ is a broad term, and encompasses the individual’s ability to... Content action menuShareTestTest 2Test 3
Schizophrenia Article Treatment-resistant schizophrenia – results of a survey on its clinical impact and therapeutic strategies The results of an online survey completed by 204 US psychiatrists on the clinical impact of... Content action menuShareTestTest 2Test 3
Depression Article Brain circuits in depression and response to pharmacotherapy The symptoms of major depressive disorder (MDD) vary from patient to patient. The primary treatment... Content action menuShareTestTest 2Test 3
Schizophrenia Article Steps towards more effective and better tolerated treatment options for schizophrenia New more effective and better tolerated treatments for schizophrenia are needed to improve patient... Content action menuShareTestTest 2Test 3